

ASX RELEASE

12 September 2022

CEO Resignation

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) wishes to advise that CEO and Managing Director, Dr John Lambert, has given notice of his resignation to the Board. It is expected that Dr Lambert will leave the Company in November 2022 but will be available to assist with an orderly transition of the role.

Amplia’s Chair, Dr Warwick Tong, stated that “The Amplia Board would like to thank John for his contributions to Amplia over the last four years and we wish him well with the next stage of his career. John has successfully led Amplia through the major and important transition from a pre-clinical stage company to one with clinical stage programs. Our lead asset, AMP945, recently started a Phase 2 clinical trial in patients with pancreatic cancer and a second Phase 2 trial in pulmonary fibrosis is in advanced preparation. We will be seeking to identify a new CEO with the ability to build on the established clinical development capability and to take the Company to its next stage.”

Dr Lambert commented that “It has been a great privilege to serve as CEO of Amplia for the last few years and I am incredibly proud to have overseen the growth of Amplia over that time. I am pleased to have built an outstanding team with the resources to progress the pipeline to significant value inflexions. There are even more exciting times ahead for Amplia but I feel that it is an appropriate time for an executive leadership transition and for me to seek new challenges. I have enjoyed exceptional support from the Board and I thank them for their guidance and oversight during my time as CEO.”

The search for a new CEO will commence immediately and it is both the Board’s and Dr Lambert’s desire to manage the transition smoothly and without interruption to the Company’s operations.

This ASX announcement has been approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Dr. Warwick Tong

Chair

info@ampliatx.com

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).